DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting. Endo provided funding through an investigator-initiated research grant..

都柏林，2024年1月19日/PRNewswire/--Endo International plc（OTC:ENDPQ）今天宣布，在美国手外科协会（AAHS）年会上，分享了与Dupuytren挛缩和XIAFLEX®（胶原酶溶组织梭菌）相关的两篇新演讲。Endo通过研究者发起的研究资助提供资金。。

'This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes,' said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.

佛罗里达州坦帕市佛罗里达骨科研究所（Florida Orthopaedic Institute）的整形外科医生杰森·尼迪克（JasonNydick）博士（Dr.JasonNydick）说，在AAHS年会上介绍的这些医学知识可能有助于医疗保健提供者治疗Dupuytren挛缩患者，并有望改善患者的预后。

'The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy.'.

“与XIAFLEX有效治疗近端指间（PIP）关节相关的结果特别值得注意。”。

The two new Endo-supported research presentations are below:

Endo支持的两个新的研究报告如下：

Clinical Effectiveness of Splinting After Collagenase Clostridium Histolyticum Injection for Dupuytren's Contracture

溶组织梭菌胶原酶注射后夹板固定治疗Dupuytren挛缩的临床疗效

Authors: Craig Dent, MS; Nino Coutelle, MD; Meera Gill, DO; Peter Simon, PhD; Jason Nydick, DO

作者：Craig Dent，MS；医学博士Nino Coutelle；米拉·吉尔，DO；彼得·西蒙博士；杰森·尼迪克

Investigator-initiated research funding grant provided by Endo

Endo提供的研究者发起的研究资助

Clinical Outcomes of Collagenase Injections in Management of Dupuytren's Contracture of the Proximal Interphalangeal Joint

胶原酶注射治疗近端指间关节Dupuytren挛缩的临床疗效

Authors: Craig Dent, MS; Nino Coutelle, MD; Andrew Moore, MD; Matthew Nester, BS; Peter Simon, PhD; Jason Nydick, DO

作者：Craig Dent，MS；医学博士Nino Coutelle；安德鲁·摩尔，医学博士；Matthew Nester，理学学士；彼得·西蒙博士；杰森·尼迪克

Investigator-initiated research funding grant provided by Endo

Endo提供的研究者发起的研究资助

About Dupuytren's ContractureDC is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. As DC progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities..

关于Dupuytren的挛缩症是一种终身疾病，可能会随着时间的推移而恶化。它是由手部胶原蛋白的积累引起的，胶原蛋白形成了一条绳索状的绳索，将手指拉向手掌，使手指无法伸直。随着DC的发展，个人可能难以用手完成日常任务和活动。。

WHAT IS XIAFLEX®?

什么是XIAFLEX®？

XIAFLEX is a prescription medicine used to treat adults with Dupuytren's contracture when a 'cord' can be felt. It is not known if XIAFLEX is safe and effective in children under the age of 18.

XIAFLEX是一种处方药，用于治疗成年人Dupuytren挛缩时可以感觉到“绳索”。目前尚不清楚XIAFLEX对18岁以下儿童是否安全有效。

IMPORTANT SAFETY INFORMATION FOR XIAFLEX

XIAFLEX的重要安全信息

Do not receive XIAFLEX if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.

如果您对溶组织梭菌胶原酶或XIAFLEX中的任何成分或任何其他胶原酶产品有过敏反应，请不要服用XIAFLEX。有关XIAFLEX中成分的完整列表，请参阅药物指南的末尾。

XIAFLEX can cause serious side effects, including:

XIAFLEX会产生严重的副作用，包括：

Tendon rupture or ligament damage. Receiving an injection of XIAFLEX may cause damage to a tendon or ligament in your hand and cause it to break or weaken. This could require surgery to fix the damaged tendon or ligament. Call your healthcare provider right away if you have trouble bending your injected finger (towards the wrist) after the swelling goes down or you have problems using your treated hand after your follow-up visit.

肌腱断裂或韧带损伤。注射XIAFLEX可能会损伤手部肌腱或韧带，导致其断裂或减弱。这可能需要手术来修复受损的肌腱或韧带。如果肿胀消退后无法弯曲注射的手指（朝向手腕），或者在随访后无法使用治疗过的手，请立即致电医疗保健提供者。

Nerve injury or other serious injury of the hand. After finger procedures, some people developed tears in the skin (lacerations), and local skin and soft-tissue necrosis (death of skin cells). Some lacerations and necrosis required skin grafting, or other surgery including amputation. Call your healthcare provider right away if you get numbness, tingling, increased pain, or tears in the skin (laceration) in your treated finger or hand after your injection or after your follow-up visit.

神经损伤或手部其他严重损伤。手指手术后，一些人出现皮肤撕裂（撕裂），局部皮肤和软组织坏死（皮肤细胞死亡）。一些裂伤和坏死需要植皮或其他手术，包括截肢。如果注射后或随访后，您的手指或手出现麻木、刺痛、疼痛加剧或皮肤撕裂（裂伤），请立即致电您的医疗保健提供者。

Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX because it contains foreign proteins. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:

超敏反应，包括过敏反应。服用XIAFLEX的人可能会发生严重的过敏反应，因为它含有外源蛋白质。如果注射XIAFLEX后出现任何过敏反应症状，请立即致电您的医疗保健提供者：

hives

蜂箱

swollen face

肿胀的脸

breathing trouble

呼吸困难

chest pain

胸痛

low blood pressure

低血压

dizziness or fainting

头晕或晕厥

Fainting. Fainting (passing out) or near fainting can happen in people who receive XIAFLEX, especially following finger proceduresIf you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away.

昏厥。服用XIAFLEX的人可能会晕厥（昏厥）或接近晕厥，尤其是在手指手术后如果您在服用XIAFLEX后感到头晕或晕厥，请躺下直到症状消失。

Increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.

出血的机会增加。注射部位出血或瘀伤可能发生在接受XIAFLEX的人身上。如果你的血液凝固有问题，请咨询你的医疗保健提供者。XIAFLEX可能不适合您。

Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, or have a bleeding problem or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

在接受XIAFLEX之前，告诉您的医疗保健提供者您是否对之前的XIAFLEX注射有过敏反应，或有出血问题或任何其他医疗状况。告诉你的医疗保健提供者你服用的所有药物，包括处方药和非处方药、维生素和草药补充剂。

Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner.

将XIAFLEX与某些其他药物一起使用可能会产生严重的副作用。特别是告诉你的医疗保健提供者，如果你服用药物来稀释血液（抗凝剂）。如果在注射XIAFLEX之前被告知停止服用血液稀释剂，您的医疗保健提供者应该告诉您何时重新启动血液稀释剂。

Ask your healthcare provider or pharmacist for a list of these medicines if you are unsure..

如果您不确定，请向您的医疗保健提供者或药剂师索取这些药物的清单。。

The most common side effects with XIAFLEX for the treatment of Dupuytren's contracture include:

XIAFLEX治疗Dupuytren挛缩最常见的副作用包括：

swelling of the injection site or the hand

注射部位或手肿胀

bruising or bleeding at the injection site

注射部位有瘀伤或出血

pain or tenderness of the injection site or the hand

注射部位或手部疼痛或压痛

swelling of the lymph nodes (glands) in the elbow or armpit

肘部或腋窝淋巴结（腺体）肿胀

itching

瘙痒

breaks in the skin

皮肤破裂

redness or warmth of the skin

皮肤发红或发热

pain in the armpit

腋下疼痛

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.

如果你有任何副作用困扰你或没有消失，请告诉你的医疗保健提供者。这些并不是XIAFLEX可能产生的所有副作用。有关更多信息，请咨询您的医疗保健提供者或药剂师。

Click for full Prescribing Information, including Medication Guide.

单击以获取完整的处方信息，包括用药指南。

About EndoEndo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward.

关于EndoEndo（OTC:ENDPQ）是一家专业制药公司，致力于通过提供优质的改善生活的疗法，帮助我们服务的每一个人过上最好的生活。我们数十年的成功经验来自全球充满激情的团队成员，他们合作推进治疗。

Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn..

在一起，我们大胆地将见解转化为有利于需要的人的治疗方法，当他们需要时。请访问www.endo.com了解更多信息，或通过LinkedIn与我们联系。。

Cautionary Note Regarding Forward-Looking StatementsCertain information in this press release may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Dr.

关于前瞻性声明的注意事项本新闻稿中的某些信息可能被视为1995年《私人证券诉讼改革法案》和任何适用的加拿大证券立法（包括但不限于Dr。

Nydick, any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'plan,' 'will,' 'may,' 'look forward,' 'intend,' 'guidance,' 'future,' 'potential' or similar expressions are forward-looking statements.

Nydick，与产品功效，潜在治疗或适应症，治疗结果或治疗反应有关的任何声明，以及提及预期，估计或预期未来结果或不完全与历史事实相关的任何声明。包括“相信”、“期望”、“预期”、“打算”、“估计”、“计划”、“意志”、“可能”、“展望”、“打算”、“指导”、“未来”、“潜在”等词语或短语的陈述都是前瞻性陈述。

All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; any actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the risks and uncertainties associated with chapter 11 proceedings; the time, terms and ability to complete a chapter 11 plan of reorganization or to.

本通讯中的所有前瞻性陈述反映了截至本通讯之日，公司对其计划、意图、期望、战略和前景的当前观点，这些观点是基于目前可获得的信息及其做出的假设。基于多种因素，实际结果可能与当前预期存在重大不利差异，其中包括公司应急计划和重组活动的结果；任何未决或未来诉讼、调查、诉讼或索赔的时间、影响或结果，包括阿片类药物、税务和反托拉斯相关事项；任何实际或或有负债；和解讨论或谈判；公司的流动性、财务业绩、现金状况和运营情况；与第11章诉讼相关的风险和不确定性；完成第11章重组计划的时间、条件和能力。

Additional information concerning risk factors, including those referenced above, can be found in press releases issued by the Company, as well as the Company's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S.

有关风险因素（包括上述风险因素）的其他信息，请参阅公司发布的新闻稿，以及公司向美国证券交易委员会和加拿大证券监管机构定期提交的公开文件，包括公司最新的10-K表年度报告和随后的10-Q表季度报告或向美国提交的其他文件中“风险因素”标题下的讨论。

Securities and Exchange Commission..

美国证券交易委员会。。

SOURCE Endo International plc

来源Endo International plc